Immunotherapy (PD-1 Inhibitors e.g., Pembrolizumab/Nivolumab)
Treatment for Malignant Neoplasm Of Bone And Articular Cartilage
Typical Dosage: e.g., Pembrolizumab 200 mg IV every 3 weeks
Effectiveness
40%
Safety Score
60%
Clinical Trials
20
Participants
1K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
e.g., Pembrolizumab 200 mg IV every 3 weeks
Time to Effect
1-3 months
Treatment Duration
Until progression or unacceptable toxicity (months to years)
Evidence Quality
LOWConfidence Score
40%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$180,000
Monitoring:$10,000
Side Effect Mgmt:$5,000
Total Annual:$195,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.3
Outcome-Based Costs
Cost per Responder
$1,300,000
Cost per Remission
$6,500,000
Comparison vs Chemotherapy (second-line)
Cost Difference
+$50,000/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Immunotherapy (PD-1 Inhibitors e.g., Pembrolizumab/Nivolumab) Outcomes
for Malignant Neoplasm Of Bone And Articular Cartilage
Efficacy Outcomes
Overall Effectiveness
+40%
Response Rate
+15%
Remission Rate
+3%
Common Side Effects
Fatigue
+40%
Rash/Pruritus
+30%
Diarrhea/Colitis
+15%
Hypothyroidism
+10%
Pneumonitis
+3%
Other immune-related adverse events
+5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov